BrandWikiReturn

Nicholas Lydon

Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur.[1] In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.[2][3][4][5][6]

Education

Lydon was educated at Strathallan School near Perth, Scotland.[7] He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his PhD in biochemistry from the University of Dundee, Scotland in 1982.[7][8]

Career

In 1982, Lydon accepted a position with Schering-Plough based in France as Chargé de Récherche.[3] Three years later, he moved to Switzerland to work with Ciba-Geigy Pharmaceuticals, with whom he developed Gleevec.[7] In 1997, he established Kinetex Pharmaceuticals in Boston which was acquired by Amgen in 2000, with whom he worked until 2002.[7] Thereafter, he established several companies that continue to develop drugs to treat various conditions.[7]

Honours and awards

Lydon's nomination for the Royal Society reads:

  • Warren Alpert Foundation Prize, 2000.[3]
  • Twenty First Annual AACR-Bruce F. Cain Memorial Award, 2002.[3]
  • Charles F. Kettering Prize, General Motors Cancer Research Foundation, 2002.[3]
  • The Lasker-DeBakey Clinical Medical Research Award, with Brian Druker and Charles Sawyers, 2009.[3]
  • The Japan Prize, with Brian Druker and Janet Rowley, 2012.[3]
  • Fellow of the Royal Society, 2013.[9]
  • Royal Society GlaxoSmithKline Prize and Lecture, 2014[10]

References

  1. Nicholas Lydon www.scienceheroes.com, 2010, retrieved 13 February 2013^
  2. Lasker – DeBakey Clinical Medical Research Award: Award Description Lasker Foundation, retrieved 16 August 2010^
  3. Laureates of the Japan Prize The Japan Prize Foundation, 2012, retrieved 13 February 2013^
  4. B. J. Druker, M. Talpaz, D. J. Resta, B. Peng, E. Buchdunger, J. M. Ford, N. B. Lydon, H. Kantarjian. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia New England Journal of Medicine, 2001^
  5. B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, N. B. Lydon. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nature Medicine, 1996^
  6. E. Buchdunger, C. L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B. J. Druker, N. B. Lydon. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors The Journal of Pharmacology and Experimental Therapeutics, 2000^
  7. Dr Nicholas Lydon University of Dundee, 2011, retrieved 13 February 2013^
  8. Nicholas B. Lydon. Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum University of Dundee, 1982^
  9. Dr Nicholas Lydon Royal Society, 2013, retrieved 29 May 2013^
  10. GlaxoSmithKline prize Royal Society, retrieved 12 September 2013^